Pharmaceutical Executive July 9, 2024
Approval of the Mynx Control Venous vascular closure device was based on results from the ReliaSeal trial, which demonstrated 100% procedural and device success in cardiac ablation procedures.
The FDA has approved Cordis’ Mynx Control VenousVascular Closure Device (VCD), designed for cardiac ablation procedures with access sites ranging from 6F to 12F. According to the company, the device utilizes grip technology, which leverages a hydrophilic, bioinert polyethylene glycol (PEG) sealant that resorbs three times faster than collagen-based alternatives and reportedly provides the fastest time to hemostasis among venous closure devices. Additionally, the device was approved based on promising results from the ReliaSeal trial, which found that the Mynx Control VenousVCD demonstrated 100% procedural and device success in cardiac ablation procedures.1
...Today's Sponsors
Today's Sponsor